ロード中...
Atenolol and bendrofluazide in hypertension.
The effect of atenolol, a new beta-1-adrenergic receptor blocking agent, was studied in a double-blind cross-over trial in 24 carefully selected hypertensive outpatients. After a four-week run-in period on matching placebo each patient received atenolol 200 mg/day, atenolol 400 mg/day, a combination...
保存先:
| 主要な著者: | , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
1975
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1674832/ https://ncbi.nlm.nih.gov/pubmed/1104047 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|